Canopy Growth's Medical Marijuana Sales Are Soaring. Is the Beaten-Down Stock Ready to Rebound?

Canopy Growth posted another loss in fiscal 2026, with gross margin down 6 percentage points for the full year and 4 points in the fourth quarter. Medical marijuana revenue rose 27% in Q4 and 17% for the year, but recreational cannabis grew just 1% in Q4, international cannabis sales fell 7% year over year, and Storz & Bickel sales declined 14%. The company also recapitalized its balance sheet by exchanging shares for debt, reinforcing a cautious outlook despite strength in one division.

Analysis

The core message is not that the business is collapsing, but that the equity is becoming increasingly dependent on a single profit pool while the rest of the portfolio is either stalling or structurally dilutive. That matters because in low-visibility consumer discretionary names, the market typically pays for durability of cash flow, not isolated pockets of growth; once one segment is carrying the narrative, multiple compression tends to follow as investors haircut the persistence of those margins.

The larger second-order issue is channel economics. Weakness in recreational and vaporizer volumes suggests the company may be relying on promo intensity or product mix shifts to defend share, which usually shows up with a lag in gross margin before it is visible in top-line growth. If that dynamic persists for another 1-2 quarters, the market is likely to treat the current medical growth as simply offsetting shrinkage elsewhere rather than creating incremental enterprise value.

The balance-sheet recap adds an important overhang: equity issuance or share-based deleveraging can buy time, but it also raises the hurdle for future per-share upside because any operating recovery is diluted before it reaches owners. In a name like this, the catalyst set is asymmetric: upside requires not just segment stabilization but margin inflection and credible path to positive earnings, while downside can reassert quickly if medical growth normalizes or integration costs from M&A leak into gross margin.

Consensus may be underestimating how much of the good news is already familiar to holders, while underestimating the speed at which a "one strong segment" story gets rerated back into a distressed balance-sheet trade. The stock can still squeeze on sentiment, but sustainable revaluation likely needs 2-3 consecutive quarters of gross margin recovery and broad-based volume improvement; absent that, rallies are more likely to be sold into than extended.

Key Decisions for Investors

• Avoid initiating long CGC on headline strength; if already long, use any post-earnings spike to reduce exposure over the next 1-2 weeks while the market is still digesting margin compression.
• For aggressive traders, consider a short-dated CGC put spread into the next quarterly report: downside is defined, and the setup favors a negative reaction if gross margin or recreational volumes fail to inflect.
• Pair trade idea: short CGC vs. long a higher-quality cannabis operator with steadier margins and cleaner balance sheet execution over a 1-3 month horizon; the thesis is dispersion in capital discipline, not sector direction.
• If entering long, wait for evidence of two consecutive quarters of gross margin stabilization and international sales normalization; otherwise the risk/reward remains skewed toward value traps rather than a durable rerating.